Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$12.4MFederal grants as PI12 awards
8Patents grantedLatest May 19, 2026
69Papers2,687 citations
Federal awards and patents by year
AwardsPatents
12 awards · $12.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 22, 2021 | NIH | SBIR Phase I Kinase activation in multiple system atrophy | $386K | Inhibikase Therapeutics, Inc. |
| Jul 23, 2020 | NIH | SBIR Phase II Advanced therapeutic for Parkinson's Disease | $1.5M | Inhibikase Therapeutics, Inc. |
| Sep 17, 2019 | NIH | SBIR Phase II Advanced therapeutic for Parkinson's Disease | $1.6M | Inhibikase Therapeutics, Inc. |
| Jul 18, 2019 | NIH | SBIR Phase II Advanced Prodrug Treatment for CML | $986K | Inhibikase Therapeutics, Inc. |
| Sep 17, 2018 | NIH | SBIR Phase II Advanced Prodrug Treatment for CML | $1.0M | Inhibikase Therapeutics, Inc. |
| Aug 2, 2018 | NIH | SBIR Phase II Advanced therapeutic for Parkinson's Disease | $1.6M | Inhibikase Therapeutics, Inc. |
| Feb 7, 2018 | NIH | SBIR Phase II Advanced PML antiviral | $1.0M | Inhibikase Therapeutics, Inc. |
| Sep 18, 2017 | NIH | SBIR Phase I Prodrug treatment for CML | $285K | Inhibikase Therapeutics, Inc. |
| Aug 24, 2017 | NIH | SBIR Phase II Advanced therapeutic for Parkinson's Disease | $1.6M | Inhibikase Therapeutics, Inc. |
| Feb 7, 2017 | NIH | SBIR Phase II Advanced PML antiviral | $1.0M | Inhibikase Therapeutics, Inc. |
| Jun 3, 2016 | NIH | SBIR Phase II Novel DFG out inhibitors of Abl-kinases to treat PML | $788K | Inhibikase Therapeutics, Inc. |
| Jun 15, 2015 | NIH | SBIR Phase II Novel DFG out inhibitors of Abl-kinases to treat PML | $753K | Inhibikase Therapeutics, Inc. |
9 patents as inventor
- US 10118923Inhibikase Therapeutics, Inc.Nov 6, 2018
- US 10316031Inhibikase Therapeutics, Inc.Jun 11, 2019
- US 10344027Inhibikase Therapeutics, Inc.Jul 9, 2019
- US 10906896Inhibikase Therapeutics, Inc.Feb 2, 2021
- US 11407747Inhibikase Therapeutics, Inc.Aug 9, 2022
- US 11725005Inhibikase Therapeutics, Inc.Aug 15, 2023
- US 12629371Inhibikase Therapeutics, Inc.May 19, 2026
- US 9828370Inhibikase Therapeutics, Inc.Nov 28, 2017
- US Inhibikase Therapeutics, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#36
Awards as PI#86
Patents#6
Companies
- Inhibikase Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.